Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device. It also customizes the Omnipod System technology platform for the delivery of drugs over a specified interval of time, at an administered volume. The company sells and markets its Omnipod System through a combination of direct sales representatives and independent distributors. Insulet Corporation was founded in 2000 and is headquartered in Billerica, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:PODD
Previous Symbol
CUSIP45784P10
Phone978-600-7000
Debt
Debt-to-Equity Ratio2.95
Current Ratio4.58
Quick Ratio3.99
Price-To-Earnings
Trailing P/E Ratio-172.59
Forward P/E Ratio-1,587.80
P/E GrowthN/A
Sales & Book Value
Annual Sales$463.77 million
Price / Sales10.11
Cash FlowN/A
Price / CashN/A
Book Value$3.35 per share
Price / Book23.70
Profitability
EPS (Most Recent Fiscal Year)($0.46)
Net Income$-26,830,000.00
Net Margins-2.54%
Return on Equity-7.63%
Return on Assets-1.60%
Miscellaneous
Employees857
Outstanding Shares59,080,000
Market Cap$4.85 billion
OptionableOptionable
Insulet (NASDAQ:PODD) Frequently Asked Questions
What is Insulet's stock symbol?
Insulet trades on the NASDAQ under the ticker symbol "PODD."
How were Insulet's earnings last quarter?
Insulet Co. (NASDAQ:PODD) posted its earnings results on Thursday, November, 1st. The medical instruments supplier reported $0.03 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.02 by $0.01. The medical instruments supplier had revenue of $151.10 million for the quarter, compared to analyst estimates of $148.82 million. Insulet had a negative return on equity of 7.63% and a negative net margin of 2.54%. Insulet's revenue was up 24.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.04) EPS. View Insulet's Earnings History.
When is Insulet's next earnings date?
What guidance has Insulet issued on next quarter's earnings?
Insulet issued an update on its first quarter 2018 earnings guidance on Thursday, November, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $159-164 million, compared to the consensus revenue estimate of $161.1 million.Insulet also updated its FY 2018 guidance to EPS.
What price target have analysts set for PODD?
15 analysts have issued 12-month price targets for Insulet's shares. Their predictions range from $80.00 to $130.00. On average, they expect Insulet's share price to reach $99.9286 in the next twelve months. This suggests a possible upside of 25.9% from the stock's current price. View Analyst Price Targets for Insulet.
What is the consensus analysts' recommendation for Insulet?
15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 3 hold ratings, 11 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Insulet.
What are Wall Street analysts saying about Insulet stock?
Here are some recent quotes from research analysts about Insulet stock:
- 1. According to Zacks Investment Research, "Insulet has been outperforming its industry over the past year. We are encouraged by the year-over-year improvement in net loss and revenues on solid uptake of Omnipod system in the United States in the last reported quarter. Expanding global customer base also drove revenues. Furthermore, expanding gross margin buoys optimism. We are also upbeat about Insulet’s solid progress with respect to its four-pillar strategy. Further, the receipt of FDA nod for the company’s Omnipod DASH Insulin Management System boosts investor confidence. Meanwhile, management expects the shifting to direct operations in Europe to continue to mar international revenues. Moreover, Insulet is exposed to risks associated with a weaker global economy and lower reimbursement rates." (10/4/2018)
- 2. Canaccord Genuity analysts commented, "We maintain our BUY rating on PODD following the announcement that the company has secured two new OUS distributor partnerships with Theras Group (Italy) and Nordic Infucare (Nordic countries) effective July 1, 2018. Both distributors will provide sales, marketing, and customer support in their respective regions. We are encouraged to see PODD not only executing on OUS transition milestones but securing experienced medical device distributors in OUS countries. We believe the market exit by JNJ/Animas has created a unique opportunity for pump players – basically everyone ex Medtronic – to step into existing distribution/service networks who were left looking for new products when JNJ announced it was shuttering Animas. Thus, while not underestimating the resources required to build out an OUS commercial organization, the news of these two partnerships leaves us incrementally confident in Insulet’s ability to facilitate a smooth OUS transition." (5/2/2018)
Has Insulet been receiving favorable news coverage?
Headlines about PODD stock have trended somewhat positive on Thursday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Insulet earned a news impact score of 1.7 on InfoTrie's scale. They also gave media stories about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near future.
Who are some of Insulet's key competitors?
Some companies that are related to Insulet include ABIOMED (ABMD), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hill-Rom (HRC), Haemonetics (HAE), Globus Medical (GMED), Penumbra (PEN), Integra Lifesciences (IART), ICU Medical (ICUI), Cantel Medical (CMD), Merit Medical Systems (MMSI), NuVasive (NUVA), Novocure (NVCR) and Glaukos (GKOS).
Who are Insulet's key executives?
Insulet's management team includes the folowing people:
- Mr. Patrick J. Sullivan, Chairman & CEO (Age 66)
- Ms. Shacey Petrovic, Pres, COO & Director (Age 44)
- Mr. Michael L. Levitz, Sr. VP, CFO & Treasurer (Age 44)
- Mr. Charles Alpuche, Exec. VP & Chief Operations Officer (Age 58)
- Dr. Aiman Abdel-Malek, Exec. VP & Chief Technology Officer (Age 60)
Who are Insulet's major shareholders?
Insulet's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (14.86%), Capital Research Global Investors (7.09%), Frontier Capital Management Co. LLC (3.31%), William Blair Investment Management LLC (3.17%), Capital World Investors (1.19%) and American Century Companies Inc. (1.19%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Bradley A Thomas, Charles Alpuche, David A Lemoine, James C Mullen, Jessica Hopfield, John A Fallon, Joseph S Zakrzewski, Michael P Spears, Patrick J Sullivan, Regina O Sommer and Shacey Petrovic. View Institutional Ownership Trends for Insulet.
Which major investors are selling Insulet stock?
PODD stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Capital Research Global Investors, Frontier Capital Management Co. LLC, Loomis Sayles & Co. L P, KAMES CAPITAL plc, Lisanti Capital Growth LLC, Advisory Research Inc. and Franklin Resources Inc.. Company insiders that have sold Insulet company stock in the last year include Aiman Abdel-Malek, Bradley A Thomas, Charles Alpuche, David A Lemoine, John A Fallon, Michael P Spears and Shacey Petrovic. View Insider Buying and Selling for Insulet.
Which major investors are buying Insulet stock?
PODD stock was purchased by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, American Century Companies Inc., Russell Investments Group Ltd., Columbus Circle Investors, Capital International Investors, First Trust Advisors LP, Wasatch Advisors Inc. and Oak Ridge Investments LLC. Company insiders that have bought Insulet stock in the last two years include Bradley A Thomas, Charles Alpuche, James C Mullen, Jessica Hopfield, Michael P Spears and Patrick J Sullivan. View Insider Buying and Selling for Insulet.
How do I buy shares of Insulet?
Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Insulet's stock price today?
One share of PODD stock can currently be purchased for approximately $79.39.
How big of a company is Insulet?
Insulet has a market capitalization of $4.85 billion and generates $463.77 million in revenue each year. The medical instruments supplier earns $-26,830,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis. Insulet employs 857 workers across the globe.
What is Insulet's official website?
How can I contact Insulet?
Insulet's mailing address is 600 TECHNOLOGY PARK DRIVE SUITE 200, BILLERICA MA, 01821. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]
MarketBeat Community Rating for Insulet (NASDAQ PODD)
MarketBeat's community ratings are surveys of what our community members think about Insulet and other stocks. Vote "Outperform" if you believe PODD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PODD will underperform the S&P 500 over the long term. You may vote once every thirty days.
